BALAXI PHARMACEUTICALS
NSE: BALAXI · ISIN INE618N01022 · Healthcare
₹22.50+0.16 (+0.72%)
Monday 9 November, 11:59 IST. Delayed. Source: Yahoo Finance.
Price chart
₹22.50 +0.16 (+0.72%) today
The day
- Previous close
- ₹22.34
- Open
- ₹22.64
- Day high
- ₹22.64
- Day low
- ₹22.10
Listed on NSE since 30 November 2015.
Key numbers
- Market value
- ₹121.24 Cr
- P/E (trailing)
- 48.80
- EPS (trailing)
- ₹0.45
- Price to book
- 0.49
- Dividend yield
- 0.00%
- Debt to equity
- 0.23
- Profit margin
- 0.9%
- Beta
- 0.74
- Volume today
- 7,384
- Average volume
- 36,102
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹336.43 Cr | ₹45.96 Cr |
| FY24 | ₹241.29 Cr | ₹-2.39 Cr |
| FY25 | ₹292.56 Cr | ₹25.07 Cr |
| FY26 | ₹270.17 Cr | ₹1.42 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported. EPS before FY25 is not shown: the share count changed (a bonus, split or merger), so earlier figures would not compare.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | ₹81 Cr | ₹0 | – |
| Q4 FY26Jan–Mar 2026Audited | ₹71 Cr | ₹61.28 L | −92.9% |
| Q3 FY26Oct–Dec 2025 | ₹73 Cr | ₹30.50 L | – |
| Q2 FY26Jul–Sep 2025 | ₹56 Cr | ₹20.90 L | – |
| Q1 FY26Apr–Jun 2025 | ₹71 Cr | ₹0 | – |
| Q4 FY25Jan–Mar 2025Audited | ₹76 Cr | ₹9 Cr | – |
Source: BALAXI PHARMACEUTICALS’s results filed with NSE, consolidated (the whole group). Net profit is the share of BALAXI PHARMACEUTICALS’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | March 2026 | September 2025 |
|---|---|---|
| Fixed assets | ₹49 Cr | ₹48 Cr |
| Inventories | ₹83 Cr | ₹78 Cr |
| Owed by customers | ₹136 Cr | ₹109 Cr |
| Cash and equivalents | ₹15 Cr | ₹39 Cr |
| Total assets | ₹337 Cr | ₹322 Cr |
| Borrowings | ₹56 Cr | ₹55 Cr |
| Total liabilities | ₹88 Cr | ₹84 Cr |
| Shareholders’ equity | ₹249 Cr | ₹238 Cr |
Source: BALAXI PHARMACEUTICALS’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About BALAXI PHARMACEUTICALS
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceutical products in India and internationally. The company offers pharmaceutical products across various therapeutic areas, including antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpaste. The company was formerly known as Balaxi Ventures Limited and changed its name to Balaxi Pharmaceuticals Limited in October 2020. The company was incorporated in 1942 and is headquartered in Hyderabad, India. Balaxi Pharmaceuticals Limited is a subsidiary of Balaxi Overseas Private Limited.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Hyderabad
- Employees
- 500
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name BALAXI PHARMACEUTICALS in the last day or two.
Dividends and corporate actions
All companies- Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share
Split · ex-date 30 May 2024
- Annual General Meeting/Dividend - Rs 0.50 Per Share
Dividend · ex-date 1 July 2022 · record date 4 July 2022
- Annual General Meeting
Action · ex-date 21 September 2017
- Annual General Meeting
Action · ex-date 22 September 2016
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.